Skip to the answer

Formoterol / Glycopyrrolate Uses, Dosage, Side Effects and Interactions

Brand name
Bevespi Aerosphere

Bevespi Aerosphere was the first formoterol / glycopyrrolate product the FDA approved, in April 2016. No generic is listed as inhalers.

First generic of Bevespi Aerosphere: our estimate, March 2031

Formoterol and glycopyrrolate is a combination inhaler used for the long-term maintenance treatment of COPD (chronic obstructive pulmonary disease).

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Aug 30, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Formoterol / GlycopyrrolateType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Formoterol / Glycopyrrolate in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Bevespi Aerosphere is a COPD maintenance inhaler that pairs two long-acting airway openers, glycopyrrolate (which blocks the signal that tightens airway muscle) and formoterol (which relaxes that muscle directly). This kind of dual inhaler is a standard COPD treatment, and Bevespi has been on the market since about 2016 and is available only as the brand. Most people tolerate it well, and dry mouth, cough or headache are the side effects they notice most. Its boxed warning says formoterol used for asthma without an inhaled steroid raises the risk of serious asthma-related events, including death, so it is strictly for COPD and never a rescue inhaler.

Key Takeaways From the HelloPharmacist Team

  • Use two puffs every morning and every evening, even on days you breathe easily, because it prevents symptoms rather than relieving them.
  • Keep your short-acting rescue inhaler with you, and get medical help promptly if you need it more often than usual.
  • Before the first use, prime it by spraying into the air several times, and re-prime it if unused for more than 7 days.
  • Never add another long-acting airway inhaler alongside it, and check with your pharmacist before starting a beta-blocker, which can tighten airways.

How we write and review this content: our editorial policy

Formoterol / Glycopyrrolate by the Numbers

Strengths
1
in one form
Makers and packagers
1
Earliest FDA record
2016
Rank by Medicaid prescriptions
#892 of 1,682 drugs
More prescriptions than 46% of the 1,682 drugs we measure
13,780 prescriptions, Q1–Q4 2025

Patient Information Guide for Formoterol / Glycopyrrolate

What It’s Used For

Formoterol and glycopyrrolate is an inhaled combination medicine for adults with COPD. Here's what the supported product is approved for:

  • Bevespi Aerosphere (inhaler): maintenance treatment of COPD (chronic obstructive pulmonary disease) — taken every day to keep airways open and reduce COPD symptoms over time
  • Bevespi Aerosphere is not approved to relieve sudden breathing attacks (acute bronchospasm) — it won't work fast enough in an emergency
  • Bevespi Aerosphere is not approved for asthma — using a LABA like formoterol without an inhaled corticosteroid in asthma carries serious risks

How It Works

Bevespi Aerosphere works through two complementary mechanisms to open and relax the airways. Glycopyrrolate is an anticholinergic — it blocks muscarinic M3 receptors on the smooth muscle lining the airways, which stops the signals that would cause the airways to squeeze shut. Formoterol is a long-acting beta2-agonist (LABA) — it activates beta2 receptors on the same airway muscle cells, triggering a chain reaction that raises levels of a chemical called cyclic AMP, which causes the muscles to relax and the airways to open. Because these two ingredients work through different pathways, their combined effect is broader than either alone.

Drug Class

Drug Class

  • Anticholinergic from glycopyrronium
  • Cholinergic Muscarinic Antagonist from glycopyrronium
  • beta2-Adrenergic Agonist from formoterol
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Formoterol / Glycopyrrolate has two active ingredients, so each class says which one it comes from.

Drug Class

Established Pharmacologic Class (EPC)
  • Anticholinergic from glycopyrronium
  • Cholinergic Muscarinic Antagonist from glycopyrronium
  • beta2-Adrenergic Agonist from formoterol

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Cholinergic Muscarinic Antagonists from glycopyrronium
  • Cholinergic Antagonists from glycopyrronium
  • Adrenergic beta2-Agonists from formoterol

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Formoterol / Glycopyrrolate in the FDA’s index.

From our Patient Information GuideBevespi Aerosphere works through two complementary mechanisms to open and relax the airways. Glycopyrrolate is an anticholinergic — it blocks muscarinic M3 receptors on the smooth muscle lining the airways, which stops the signals that would cause the airways to squeeze shut. Read How Formoterol / Glycopyrrolate Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Formoterol / Glycopyrrolate in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Antihidrotics from glycopyrronium
  • Selective beta-2-adrenoreceptor agonists from formoterol

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Bevespi Aerosphere is inhaled by mouth twice a day — once in the morning and once in the evening. Before your first use, the inhaler must be primed (releasing sprays into the air before you inhale).

If you haven't used it for more than 7 days, re-prime it before your next dose.

  • Do not take more than two inhalations twice a day
  • Do not use it as a rescue inhaler — keep a separate short-acting inhaler for sudden symptoms
  • Watch the dose counter on the inhaler and replace it when it reaches zero

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Long-term treatment of COPD (chronic obstructive pulmonary disease)

For adults
Dose 18 mcg
  • Glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg (two inhalations of glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg) twice daily in the morning and in the evening by oral inhalation

Also Do not take more than two inhalations twice daily

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects reported with Bevespi Aerosphere include:

Common side effects

  • Cough
  • Urinary tract infection
  • Headache
  • Dry mouth
  • Dizziness
  • Muscle spasms
  • Nausea
  • Fatigue
  • Rapid or irregular heartbeat (associated with formoterol)
  • Tremor (associated with formoterol)

When to get medical help

  • Call your doctor right away if your breathing suddenly gets worse or you have wheezing right after using the inhaler (paradoxical bronchospasm)
  • Seek emergency help if you have signs of a serious allergic reaction: swelling of the face, lips, or tongue, trouble breathing or swallowing, or hives
  • Contact your doctor immediately if you have eye pain, blurred vision, or see halos — these can be signs of worsening glaucoma
  • Call your doctor if you have difficulty urinating or painful urination
  • Tell your doctor if your heart is beating faster or harder than usual, or if you notice chest pain
  • Get medical help right away if you need your rescue inhaler more often than usual — this can mean your COPD is getting worse
  • Watch for signs of low potassium (muscle weakness or cramps) or high blood sugar, especially if you have diabetes

Stop using Bevespi Aerosphere and get help right away if you have sudden worsening of breathing right after using it, signs of a serious allergic reaction (swelling, hives, trouble breathing), eye pain or vision changes, or difficulty urinating — these are signs of potentially serious reactions that need prompt attention.

Warnings and Precautions

  • LABA and asthma risk: Formoterol, a LABA, must not be used in asthma without an inhaled corticosteroid — doing so increases the risk of serious asthma events and death. Bevespi Aerosphere is only approved for COPD.
  • Not a rescue inhaler: Do not use Bevespi Aerosphere for sudden breathing attacks. Always have a short-acting rescue inhaler available.
  • Paradoxical bronchospasm: In rare cases, the inhaler can cause the airways to suddenly tighten right after use. If this happens, stop using it and get help immediately.
  • Heart effects: Formoterol can raise pulse rate and blood pressure. Use with extra caution if you have coronary artery disease, heart arrhythmias, or high blood pressure.
  • Glaucoma: Glycopyrrolate can worsen narrow-angle glaucoma. Contact your doctor immediately if you develop eye pain, blurred vision, or see halos.
  • Urinary retention: Glycopyrrolate can worsen urinary problems, especially in men with an enlarged prostate. Tell your doctor if you have trouble urinating.
  • Do not exceed the recommended dose or combine with other LABA-containing medicines — overuse can cause serious, potentially fatal heart effects.

Interactions

Several medicines and drug classes can interact with formoterol and glycopyrrolate:

  • Other LABAs: Never use a second LABA alongside Bevespi Aerosphere — this increases the risk of overdose and serious cardiovascular effects
  • Other anticholinergics: Combining with other anticholinergic medicines can intensify side effects like dry mouth, urinary retention, and worsening glaucoma
  • Beta-blockers: Can block formoterol's airway-opening effect and may cause severe bronchospasm in COPD patients; only use if medically necessary
  • MAO inhibitors and tricyclic antidepressants: Can greatly amplify formoterol's effects on the heart and blood pressure — use with extreme caution
  • QTc-prolonging drugs: Medicines that affect heart rhythm may increase the risk of dangerous arrhythmias when combined with formoterol
  • Non-potassium-sparing diuretics (loop or thiazide): Can worsen the potassium-lowering effect of formoterol, which may affect the heart
  • Xanthine derivatives, steroids, or other diuretics: May add to the risk of low potassium (hypokalemia) when used with formoterol
  • Other adrenergic medicines: May amplify formoterol's stimulant effects on the heart and blood vessels

Interactions Listed in the FDA-Approved Label

From the Formoterol / Glycopyrrolate prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Other adrenergic drugs
    What happensThe sympathetic effects of formoterol may be potentiated.
    What to doUse with caution.
  • Xanthine derivatives, steroids, or diuretics
    What happensMay potentiate any hypokalemic effect of beta 2 adrenergic agonists such as formoterol.
    What to doUse with caution.
  • Non-potassium sparing diuretics For example: loop or thiazide diuretics
    What happensECG changes and/or hypokalemia can be acutely worsened by beta 2 -agonists, especially when the recommended dose of the beta 2 -agonist is exceeded.
    What to doCaution is advised in coadministration.
  • Monoamine oxidase inhibitors, tricyclic antidepressants, or other QTc prolonging drugs
    What happensThe action of adrenergic agonists on the cardiovascular system may be potentiated; drugs that prolong the QTc interval may increase the risk of ventricular arrhythmias.
    What to doAdminister with extreme caution.
  • Beta-blockers
    What happensThey may interfere with the effect of each other; beta-blockers block the therapeutic effects of beta 2 -agonists and may produce severe bronchospasm in COPD patients.
    What to doPatients with COPD should not normally be treated with beta-blockers; if needed, cardioselective beta-blockers could be considered, with caution.
  • Anticholinergics
    What happensPotential for an additive interaction, which may increase anticholinergic adverse effects.
    What to doAvoid coadministration with other anticholinergic-containing drugs.
Read the label’s full interactions text

7 DRUG INTERACTIONS No formal drug interaction studies have been performed with BEVESPI AEROSPHERE. • Other adrenergic drugs may potentiate effect: Use with caution • Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. • Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non-potassium sparing diuretics may worsen with concomitant beta 2 -agonists. • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol fumarate on cardiovascular system. • Beta-blockers: Use with caution and only when medically necessary. • Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administrations of BEVESPI AEROSPHERE with other anticholinergic-containing drugs. 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol, a component of BEVESPI AEROSPHERE, may be potentiated. 7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of beta 2 adrenergic agonists such as formoterol, a component of BEVESPI AEROSPHERE. 7.3 Non-Potassium Sparing Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta 2 -agonists, especially when the recommended dose of the beta 2 -agonist is exceeded. Approximately 17% of subjects were taking non-potassium sparing diuretics during the two 24-week placebo-controlled trials in subjects with COPD.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Allergy: Do not use if you are allergic to glycopyrrolate, formoterol fumarate, or any ingredient in Bevespi Aerosphere
  • Asthma: Do not use Bevespi Aerosphere for asthma — using a LABA without an inhaled corticosteroid in asthma can be life-threatening
  • Heart conditions: Tell your doctor if you have coronary artery disease, heart rhythm problems, or high blood pressure
  • Eye problems: Tell your doctor if you have narrow-angle glaucoma
  • Prostate or urinary problems: Tell your doctor if you have an enlarged prostate or difficulty urinating
  • Seizure disorders or thyroid disease: Mention these to your doctor before starting
  • Diabetes: Formoterol can raise blood sugar — monitor carefully and tell your doctor
  • Severe kidney disease: Use only if the benefit clearly outweighs the risk; glycopyrrolate can build up in the body
  • Liver disease: Formoterol is processed by the liver — liver problems may cause it to accumulate; monitor closely
  • Pregnancy: No adequate human studies exist; discuss with your doctor before use, especially near delivery since beta-agonists may affect uterine contractions
  • Breastfeeding: It is not known if these medicines pass into human breast milk; discuss with your doctor
  • Children: Bevespi Aerosphere is not approved for pediatric use — safety and effectiveness in children have not been established
  • Older adults: No dose adjustment is needed based on age alone, but older individuals may be more sensitive to the medicine

Overdose

Too much Bevespi Aerosphere can cause symptoms of both glycopyrrolate and formoterol overdose. Glycopyrrolate excess may cause nausea, vomiting, blurred vision, difficulty urinating, or increased eye pressure. Too much formoterol can cause a rapid or irregular heartbeat, chest pain, high or low blood pressure, tremor, headache, seizures, low potassium, high blood sugar, or — in severe cases — cardiac arrest. If you suspect an overdose, stop using the inhaler and seek medical care immediately; cardiac monitoring is recommended.

Half-Life and How Your Body Processes It

After inhalation of Bevespi Aerosphere, glycopyrrolate reaches peak blood levels within about 5 minutes, while formoterol peaks within 20 to 60 minutes. Both medicines reach steady levels in the body within 2 to 3 days of regular twice-daily use. Glycopyrrolate is mainly cleared through the kidneys (about 85% is found in urine), while formoterol is primarily broken down by the liver and excreted in urine and stool. Both have a terminal half-life (the time for the body to clear half the drug) of about 11.8 hours. People with severe kidney disease may have significantly higher glycopyrrolate exposure, and those with liver disease may have higher formoterol levels.

Storage

Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Keep out of reach of children. Store near heat or open flame.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Formoterol / Glycopyrrolate: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Formoterol / Glycopyrrolate — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly does Bevespi Aerosphere do, and will I feel it working right away?

Bevespi Aerosphere is a maintenance inhaler — it works every day in the background to keep your airways open so COPD symptoms don't flare up. Formoterol does have a relatively quick onset compared to some LABAs, but this inhaler is not meant to act as a rescue medicine during a sudden attack. Your doctor should prescribe you a separate short-acting inhaler (like albuterol) for those moments. Over the first few days of regular use, you should start to notice easier breathing as the medicine builds up to steady levels.

Can I use my Bevespi Aerosphere when I'm having a sudden breathing attack?

No — please don't rely on it for that. Bevespi Aerosphere is designed to prevent symptoms over time, not to relieve sudden ones. For a breathing emergency, use the short-acting rescue inhaler your doctor prescribes separately. If you find yourself needing that rescue inhaler more often than usual, that's a signal your COPD may be getting worse — call your doctor.

I've heard LABAs can be dangerous in asthma. Should I be worried about taking this for my COPD?

The risk you're thinking of is real, but it applies specifically to asthma — not COPD. In people with asthma, using a LABA like formoterol without also taking an inhaled corticosteroid has been linked to serious and even fatal events. That's why Bevespi Aerosphere is only approved for COPD, not asthma. In COPD patients, available data do not show that LABAs increase the risk of death. Still, always make sure your doctor knows your full diagnosis so you're on the right treatment.

Are there any medicines I should avoid while taking Bevespi Aerosphere?

Yes, a few important ones. Don't use another inhaler that contains a long-acting beta-agonist at the same time — using two together increases the risk of serious heart side effects. Other anticholinergic medicines can compound side effects like dry mouth and urinary problems. If you take MAO inhibitors or certain antidepressants, let your doctor know, because those can intensify the heart effects of formoterol. Beta-blockers (common for heart conditions) can also reduce how well Bevespi works and can trigger airway tightening. Always share your full medication list with your pharmacist or doctor.

What side effects are most likely, and when should I call my doctor?

The most common side effects are cough and urinary tract infections. Some people also notice dry mouth, headache, dizziness, or muscle spasms. These are usually manageable. Call your doctor right away if you have sudden worsening of breathing right after using the inhaler, eye pain or vision changes, trouble urinating, a racing or pounding heartbeat, or signs of an allergic reaction like swelling of the face or lips. These could signal something more serious that needs prompt attention.

How do I know when my inhaler is running out, and is there anything special about setting it up?

Bevespi Aerosphere has a built-in dose counter that shows how many inhalations are left — the display turns red when you're getting close to the end. When it reaches zero, discard the inhaler. Before your very first use, you need to prime it by shaking well and releasing 4 sprays into the air (away from your face). If you haven't used it for more than 7 days, re-prime with 2 sprays. This makes sure each puff delivers the right amount of medicine.

Is formoterol / glycopyrrolate available over the counter?

No. Formoterol / glycopyrrolate is a prescription medicine: every formoterol / glycopyrrolate product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was formoterol / glycopyrrolate first available?

The earliest FDA record we hold for formoterol / glycopyrrolate is from 2016: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when formoterol / glycopyrrolate was first used.

What is the brand name of formoterol / glycopyrrolate?

Formoterol / glycopyrrolate is the generic name. Its brand name is Bevespi Aerosphere.

What is the generic name of Bevespi Aerosphere?

The generic name of Bevespi Aerosphere is formoterol / glycopyrrolate. A generic name is the name of the active ingredients, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is formoterol / glycopyrrolate?

Formoterol / glycopyrrolate belongs to the drug class Anticholinergic and beta2-Adrenergic Agonist, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: Cholinergic Muscarinic Antagonist.

What strengths does formoterol / glycopyrrolate come in?

Formoterol / glycopyrrolate is listed in the FDA's National Drug Code Directory in these forms and strengths. Inhaler (inhaled): 4.8 mcg/9 mcg. A listing does not mean every pharmacy stocks every strength.

How much does formoterol / glycopyrrolate cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $40.86 per gram of the GLYCOPYRROLATE 9 mcg/1; FORMOTEROL FUMARATE 4.8 mcg inhaler of brand-name Bevespi Aerosphere as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. The pharmacy prices section of this page lists every strength priced.

Where can I read the formoterol / glycopyrrolate prescribing information (package insert)?

The full FDA-approved prescribing information for formoterol / glycopyrrolate, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from AstraZeneca Pharmaceuticals LP's, revised Mar 24, 2023, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Formoterol / Glycopyrrolate

Skip the scrolling. Ask in your own words and get an answer from Formoterol / Glycopyrrolate’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Formoterol / Glycopyrrolate’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Formoterol / Glycopyrrolate on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Formoterol / Glycopyrrolate Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Formoterol / Glycopyrrolate Forms and Strengths (How It Comes)

Formoterol / Glycopyrrolate comes in 1 dose form, the inhaler. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Formoterol / Glycopyrrolate inactive ingredients by manufacturer.

Inhaler

Inhaled
Brands Bevespi Aerosphere (the first brand, 2016)
How this form is used
What it may be used for
  • Bevespi Aerosphere is used for the long-term maintenance treatment of COPD in adults
  • Bevespi Aerosphere is not for relief of sudden breathing attacks (acute bronchospasm)
  • Bevespi Aerosphere is not approved for the treatment of asthma
Important instructions
  • Bevespi Aerosphere is inhaled by mouth twice daily — once in the morning and once in the evening
  • Before first use, prime Bevespi Aerosphere by releasing 4 sprays into the air, shaking well before each spray; if not used for more than 7 days, re-prime with 2 sprays
  • Bevespi Aerosphere has a dose counter that shows remaining inhalations — discard when the counter reaches zero
  • Do not use Bevespi Aerosphere more than twice daily, and do not use it with another inhaler that contains a long-acting beta-agonist
Available strengths 1 strength
1 FDA-listed product record ⓘ

Formoterol / Glycopyrrolate on the U.S. Market: Products, Makers and Brands

How Formoterol / Glycopyrrolate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Formoterol / Glycopyrrolate product record with the FDA, mostly as inhaler; the earliest marketing or approval year on record is 2016. The one brand name in the directory today is Bevespi Aerosphere; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
1
FDA-listed product records ⓘ
2016
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished aerosol, metered (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Formoterol / Glycopyrrolate Is Used (Medicaid Data)

How many Formoterol / Glycopyrrolate prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

13,780
Medicaid prescriptions filled (Q1–Q4 2025)
$6.2M paid by Medicaid, before rebates

How commonly is Formoterol / Glycopyrrolate prescribed? Of the 1,682 medications we measure, Formoterol / Glycopyrrolate ranks #892 by Medicaid prescriptions — more than 47% of them.

Where Formoterol / Glycopyrrolate ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Formoterol / Glycopyrrolate product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

120 ACTUAT formoterol fumarate 0.0048 MG/ACTUAT / glycopyrrolate 0.009 MG/ACTUAT Metered Dose Inhaler

13,780 Medicaid prescriptions (Q1–Q4 2025) 100% of Formoterol / Glycopyrrolate prescriptions shown $6.2M paid by Medicaid, before rebates ≈ $451 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1790639

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 3 listed Formoterol / Glycopyrrolate NDCs had Medicaid claims.

Compare Formoterol / Glycopyrrolate Products

A representative set of FDA-listed product records for Formoterol / Glycopyrrolate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Inhaler
GLYCOPYRROLATE 9 mcg/1; FORMOTEROL FUMARATE 4.8 mcg Respiratory (inhalation) AstraZeneca Pharmaceuticals LP NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Formoterol / Glycopyrrolate NDCs →

Formoterol / Glycopyrrolate Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Formoterol / Glycopyrrolate recalls since July 2021.

✅No Formoterol / Glycopyrrolate recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Formoterol / Glycopyrrolate in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.

Dose forms
1
Strengths
1
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Multiple ingredients (MIN) Formoterol / Glycopyrrolate RxCUI 1790638
  1. Dose form (SCDF) Metered Dose Inhaler RxCUI 1790637
    In current FDA listings

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Formoterol / Glycopyrrolate Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Formoterol / Glycopyrrolate: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

How the Pharmacy Price Has Changed

Pick a strength to see how its price has changed since Nov 2023.

Strength

For brand-name Bevespi Aerosphere, the GLYCOPYRROLATE 9 mcg/1; FORMOTEROL FUMARATE 4.8 mcg inhaler, pharmacies paid an average of $40.86 per gram as of Nov 18, 2026, up 2.7% from $39.79 a year earlier.

What pharmacies pay now
$40.86
per gram, as of Nov 18, 2026
Last 4 weeks
No change
from $40.86 on Oct 21, 2026
Last 12 months
Up 2.7%
from $39.79 on Nov 19, 2025
Lowest and highest since Nov 2023
$37.60 to $40.99
per gram

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Bevespi Aerosphere GLYCOPYRROLATE 9 mcg/1; FORMOTEROL FUMARATE 4.8 mcg inhaler: the average pharmacy price per gram, the last survey of each month
MonthPharmacy price
Nov 2026$40.86
Oct 2026$40.86
Sep 2026$40.86
Aug 2026$40.86
Jul 2026$40.87
Jun 2026$40.88
May 2026$40.86
Apr 2026$40.99
Mar 2026$40.99
Feb 2026$40.99
Jan 2026$40.99
Dec 2025$39.79
Nov 2025$39.79
Oct 2025$39.79
Sep 2025$39.78
Aug 2025$39.78
Jul 2025$39.81
Jun 2025$39.80
May 2025$39.78
Apr 2025$39.89
Mar 2025$39.89
Feb 2025$39.89
Jan 2025$39.89
Dec 2024$38.73
Nov 2024$38.73
Oct 2024$38.74
Sep 2024$38.73
Aug 2024$38.77
Jul 2024$38.76
Jun 2024$38.74
May 2024$38.75
Apr 2024$38.73
Mar 2024$38.73
Feb 2024$38.73
Jan 2024$38.73
Dec 2023$37.60
Nov 2023$37.60
FormStrengthVersion What pharmacies pay
Inhaler · Respiratory (inhalation) GLYCOPYRROLATE 9 mcg/1; FORMOTEROL FUMARATE 4.8 mcg Bevespi Aerosphere (brand) $40.86 per gram NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Formoterol / Glycopyrrolate Brand Names

Formoterol / Glycopyrrolate has one brand name on record: Bevespi Aerosphere. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Bevespi Aerosphere the first brand, 2016

Who Makes Formoterol / Glycopyrrolate: Manufacturers and Labelers

One company lists Formoterol / Glycopyrrolate products with the FDA. By number of product records, the largest are AstraZeneca Pharmaceuticals LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

AstraZeneca Pharmaceuticals LP 1

Sources for This Formoterol / Glycopyrrolate Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Mar 24, 2023, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Formoterol / Glycopyrrolate.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
AstraZeneca Pharmaceuticals LP
Linked label effective
Mar 24, 2023
Composite sections available
23
Linked SPL Set ID
ae02436e-9528-490e-a844-0c0f6f2843f9
Linked SPL Document ID
90a24746-75fb-490b-9e0d-7e33a5d8f00a
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AstraZeneca Pharmaceuticals LP is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →